Bottom line GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity
This can lead to a more even, "glowing" appearance rather than a dramatic change in base skin color
Although strict glycemic control has beneficial effects on microvascular complications (retinopathy, nephropathy or neuropathy), it does not seem to reduce the risk of cardiovascular disease, and it is associated with an increased risk of hypoglycemia in patients with DM2.3,6 Until recently, the antihyperglycemic drugs available have improved glycemic control, but without much benefits on cardiovascular and/or renal risk
They do not reverse thyroid tissue damage
The meta-analysis identified substantial heterogeneity among trials (I 2 = 99.26%), influenced by factors such as dosing variability (6003000 mg/day), differing craving assessment methods (e.g., self-report vs